ATE258801T1 - Matrixprotein zusammensetzungen um apoptose zu induzieren - Google Patents

Matrixprotein zusammensetzungen um apoptose zu induzieren

Info

Publication number
ATE258801T1
ATE258801T1 AT00906552T AT00906552T ATE258801T1 AT E258801 T1 ATE258801 T1 AT E258801T1 AT 00906552 T AT00906552 T AT 00906552T AT 00906552 T AT00906552 T AT 00906552T AT E258801 T1 ATE258801 T1 AT E258801T1
Authority
AT
Austria
Prior art keywords
induce apoptosis
matrix protein
protein compositions
enamel matrix
apoptosis
Prior art date
Application number
AT00906552T
Other languages
English (en)
Inventor
Stale Petter Lyngstadaas
Lars Hammarstroem
Stina Gestrelius
Original Assignee
Biora Bioex Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biora Bioex Ab filed Critical Biora Bioex Ab
Application granted granted Critical
Publication of ATE258801T1 publication Critical patent/ATE258801T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00906552T 1999-03-10 2000-03-09 Matrixprotein zusammensetzungen um apoptose zu induzieren ATE258801T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900336 1999-03-10
PCT/IB2000/000245 WO2000053196A1 (en) 1999-03-10 2000-03-09 Matrix protein compositions for induction of apoptosis

Publications (1)

Publication Number Publication Date
ATE258801T1 true ATE258801T1 (de) 2004-02-15

Family

ID=8092394

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906552T ATE258801T1 (de) 1999-03-10 2000-03-09 Matrixprotein zusammensetzungen um apoptose zu induzieren

Country Status (8)

Country Link
EP (1) EP1162985B1 (de)
JP (1) JP2002538211A (de)
AT (1) ATE258801T1 (de)
AU (1) AU2821000A (de)
DE (1) DE60008077T2 (de)
DK (1) DK1162985T3 (de)
ES (1) ES2215027T3 (de)
WO (1) WO2000053196A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001274374A1 (en) * 2000-06-20 2002-01-02 Biora Ab Matrix protein compositions for dentin regeneration
SE0403014D0 (sv) 2004-12-10 2004-12-10 Straumann Holding Ag New protein formulation
EP1830863A2 (de) 2004-12-10 2007-09-12 Straumann Holding AG Proteinformulierung
US8466101B2 (en) 2009-11-02 2013-06-18 Straumann Holding Ag Purified EMD protein composition
WO2011073447A1 (en) 2009-12-18 2011-06-23 Straumann Holding Ag Emd c-depleted
CA2801332C (en) 2010-10-15 2016-08-23 Straumann Holding Ag New emd formulation comprising pga
WO2012131412A2 (en) 2011-03-31 2012-10-04 Szabo Laszlo Gabor Pharmaceutical composition containing no, process for the preparation and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672032A (en) * 1983-11-09 1987-06-09 University Of Southern California Dental enamel production

Also Published As

Publication number Publication date
ES2215027T3 (es) 2004-10-01
DE60008077T2 (de) 2004-12-23
EP1162985B1 (de) 2004-02-04
AU2821000A (en) 2000-09-28
JP2002538211A (ja) 2002-11-12
EP1162985A1 (de) 2001-12-19
DK1162985T3 (da) 2004-06-14
DE60008077D1 (de) 2004-03-11
WO2000053196A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
HRP950337B1 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
TR200100054T2 (tr) Paroksetin metansülfonat
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
HUP0302913A3 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
PT1228097E (pt) Actividade antimicrobiana do primeiro grupo cationico da lactoferrina humana
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
DE60008077D1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
NO993784D0 (no) Farmasöytiske blandinger inneholdende ibuprofen og domperidon for behandling av migrene
NO20012428D0 (no) Substituerte kaprolaktamer, farmasöytiske sammensetninger som inneholder dem og deres anvendelse ved behandling av tumorer
TR201910060T4 (tr) SYN3 bileşimleri ve yöntemleri.
ZA986720B (en) Photoresponsive sunscreen compositions
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
DE69721484D1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1162985

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee